drugset / Trial / NCT03416153
Individualized Adaptive De-escalated Radiotherapy for HPV-related Oropharynx Cancer
Phase 2
Completed
91 enrolled
University of Michigan Rogel Cancer Center
National Cancer Institute (NCI) · collabVA Ann Arbor Healthcare System · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This prospective study aims to utilize pre- and mid-treatment PET-CT to guide de-escalation of radiation therapy in HPV-related squamous cell carcinoma of the oropharynx.
Timeline
- Start
- 2018-05-21
- Primary completion
- 2023-05-05
- Completion
- 2025-05-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 1 unknown | Intravenous |
| Subject | Paclitaxel | Small molecule | 30 mg/m2 | Intravenous |